Nocturnal temperature-controlled laminar airflow device for adults with severe allergic asthma: the LASER RCT

Melissa Kapoor,¹ Will Storrar,² Lara Balls,² Thomas P Brown,² Adel Mansur,³ Emma Hedley,⁴ Tom Jones,² Claire Roberts,² Beverly Shirkey,⁵ Susan Dutton,⁵ Ramon Luengo-Fernandez,⁶ Matthew Little,⁶ Ann Dewey,⁷ Sue Marshall,² Carole Fogg,²,⁷ Keith Boughton,² Najib Rahman,⁴ Ly-Mee Yu,⁸ Peter Bradding,⁹ Peter Howarth¹⁰ and Anoop J Chauhan²,⁷*

¹South East Health Technologies Alliance, Henfield, UK
²Portsmouth Hospitals NHS Trust, Respiratory Department, Portsmouth, UK
³Heartlands Hospital, Respiratory Department, Birmingham, UK
⁴Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK
⁵Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, University of Oxford, Oxford, UK
⁶Health Economics Research Centre, University of Oxford, Oxford, UK
⁷School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, UK
⁸Primary Care Trials Unit, Nuffield Department of Primary Care Health, University of Oxford, Oxford, UK
⁹Leicester Respiratory Biomedical Research Unit, Leicester, UK
¹⁰University Hospital Southampton NHS Foundation Trust, Respiratory Department, Southampton, UK

*Corresponding author anoop.chauhan@porthosp.nhs.uk

Declared competing interests of authors: Claire Roberts reports grants, in addition to non-financial support, from Novartis Pharmaceuticals UK Ltd (Frimley, UK), outside the submitted work. Peter Howarth reports part-time employment with GlaxoSmithKline plc (London, UK) as a global medical expert.

Published June 2019
DOI: 10.3310/hta23290
Scientific summary

The LASER RCT

Health Technology Assessment 2019; Vol. 23: No. 29
DOI: 10.3310/hta23290

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Asthma affects > 5.4 million people in the UK, with nearly 500,000 experiencing severe symptoms and frequent exacerbations that are inadequately controlled with available treatments. The burden of severe asthma on the NHS is enormous, accounting for 80% of the total asthma cost (£1B), with frequent exacerbations and expensive medications generating much of this cost. More than 70% of severe asthmatic patients are sensitised to common aeroallergens and the level of exposure determines symptoms; those exposed to high allergen levels are at increased risk of exacerbations and hospital admissions. Significant allergen exposure also occurs at night, when airborne particles are carried by a persistent convection current established by the warm body, transporting allergens from the bed area to the breathing zone. The temperature-controlled laminar airflow (TLA) device is effective at reducing this nocturnal allergen exposure. This trial sought to determine whether use of the TLA device when compared with placebo would lead to improvements in asthma control, inflammation and lung function and reductions in severe exacerbations in adults with severe allergic asthma.

Objective

To assess whether or not home-based nocturnal TLA treatment can effectively reduce asthma-related morbidity over a 1-year period in a real-life group of people with poorly controlled, severe allergic asthma.

Trial definition

A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial of the effectiveness of a TLA device (Airsonett®; Airsonett AB, Angelholm, Sweden) in adults with poorly controlled, severe allergic asthma.

Methods

Participants

Participants were adults (aged 16–75 years) with severe, poorly controlled, exacerbation-prone asthma despite high-intensity treatment [as defined by American Thoracic Society (ATS)/European Respiratory Society (ERS) 2013 guidance] who were sensitised to a perennial indoor aeroallergen.

Intervention

The intervention was nocturnal home-based TLA treatment using an Airsonett device, in addition to standard care, in accordance with the national British Thoracic Society/Scottish Intercollegiate Guidelines Network guidelines for the management of asthma in adults. The device is CE (Conformité Européenne) marked for use in asthma.

Primary outcome

The primary outcome was the frequency of severe asthma exacerbations occurring within the 12-month follow-up period. Severe asthma exacerbations were defined in accordance with ATS/ERS guidelines as a worsening of asthma requiring systemic corticosteroids [≥ 30 mg of prednisolone or equivalent daily (or ≥ 50% increase in dose if on a maintenance dose of ≥ 30 mg of prednisolone)] for ≥ 3 days. Courses of corticosteroids separated by ≥ 7 days were treated as separate severe exacerbations. Post hoc analyses of worsening of asthma requiring ≥ 10 mg of prednisolone or equivalent daily for ≥ 3 days were also carried out.
Secondary outcomes
Secondary outcomes included changes in asthma control, lung function and asthma-specific and global quality of life for participants, adherence to the intervention, device acceptability, health-care resource use and costs, and cost-effectiveness.

Randomisation and blinding
Participants were randomised 1:1 to TLA therapy or placebo using a validated computer randomisation program with a minimisation algorithm to ensure balanced allocation of participants across the two treatment groups for clinical site, prevalent compared with incident cases and the following prognostic factors at baseline: severe exacerbation frequency in the previous 12 months, use of maintenance oral corticosteroids and pre-bronchodilator forced expiratory volume in 1 second (FEV1).

Sample size calculation
Based on an estimated rate of two severe asthma exacerbations per participant over the 12-month period in the placebo group, determined from landmark trials of asthma, it was calculated that a minimum of 222 participants (111 per group) would be required to provide 80% power (at a 5% two-sided significance level) to detect a clinically meaningful 25% reduction in the average severe exacerbation rate in the group using the TLA device. This sample size was based on a Poisson regression model with the treatment group as the covariate and a 10% overall dropout rate. A review of comparative interventions of proven efficacy in severe asthma gave effect sizes ranging from 21% to 63%, with a mean of 41%. Given that this was a pragmatic trial in which the intervention was expected to be less effective than in an efficacy trial, a deliberately more conservative effect size of 25% was chosen. This represented, on average, one less severe exacerbation per participant every 2 years.

Monitoring and ethics
The trial was approved by the Health Research Authority: National Research Ethics Service (NRES) Committee South Central – Berkshire Research Ethics Committee [reference 14/SC/0092, Integrated Research Approval System (IRAS) project ID 148386].

Results
Patient numbers
In total, 489 patients were consented for screening between May 2014 and January 2016 across 14 trial centres in England and Northern Ireland, of whom 249 were excluded or failed both phases of screening and 240 were randomised (n = 185 from existing clinics and n = 50 from other sources); 119 participants were allocated to treatment and 121 were allocated to placebo.

A total of 202 participants (84.0%) reported use of the device for at least 9–12 months and 30 participants (12.5%) reported use of the device for < 6 months after randomisation. Of 87,840 study days reported from 240 participants, a steroid dose was reported on 58,251 days (66.3%) from the trial records and a total of 344 severe exacerbations were recorded during the trial. Carer recruitment for the trial was low and so further analyses were not performed.

Baseline characteristics
The mean baseline percentage predicted FEV1 was 69.2%, the mean baseline fraction of exhaled nitric oxide (FeNO) was 37.5 parts per billion (p.p.b.) (standard deviation (SD) 35.8 p.p.b.) and the mean severe exacerbation frequency in the previous 12 months was 3.9 per year (SD 2.9 per year). In total, 58 (24%) participants were on maintenance oral corticosteroids.

Primary outcome
There was a significant reduction in severe exacerbations in both groups from baseline to completion of the trial: from 4.3 (SD 3.7) to 1.48 (SD 2.03) per year in the placebo group and from 3.5 (SD 1.8) to
1.39 (SD 1.57) per year in the active group. An intention-to-treat mixed-effects model with a negative binomial distribution was used to estimate the difference in effects of treatment and placebo. The mean rate of severe exacerbations was not significantly different between the groups, with a risk ratio of 0.92 [95% confidence interval (CI) 0.66 to 1.27; \( p = 0.616 \)]. Sensitivity analyses including alternative sources of reported exacerbations (e.g. exacerbations recalled at a follow-up visit or a combination of dated reports and those recalled at a follow-up visit, rather than dated reports only) did not reveal any further differences between treatment groups for the primary outcome.

**Secondary outcomes**

There were no significant differences in the secondary outcomes related to lung function (pre- or post-bronchodilator FEV₁) except for a reduction in mean daily peak expiratory flow (PEF) [difference 14.7 (SD 7.35) l/minute; 95% CI 0.32 to 29.1 l/minute; \( p = 0.045 \)] in favour of the active device; there were no significant differences in asthma control (as concluded from the 7-Point Asthma Control Questionnaire and Asthma Control Diary) or airway inflammation (as measured by FeNO). There were no significant safety concerns in either group.

Qualitative analyses in both the pilot and at the end of the trial showed high levels of acceptability of the device.

**Economic evaluation**

Use of the TLA device yielded higher levels of generic and disease-specific health-related quality of life (HRQoL), with the results showing statistically significant higher HRQoL at some intermediary follow-up visits. Given that TLA use was not associated with any reduction in health-care use, these increases in HRQoL were not sufficient to offset the annual costs associated with use of the TLA device, which resulted in an incremental cost per quality-adjusted life-year (QALY) gained that was higher than the £20,000 per QALY gained threshold used by the National Institute for Health and Care Excellence (NICE) to determine cost-effectiveness.

**Conclusions**

**Main findings**

The TLA device has previously been shown to be beneficial in patients with allergic asthma, with improvements in asthma control and HRQoL. In this multicentre, randomised, placebo-controlled trial, no consistent benefits of the device over placebo were seen for severe exacerbation frequency (despite assessment of severe exacerbations from a variety of sources), asthma control or airway inflammation. There were some improvements in HRQoL at the 6-month follow-up and in PEF, but the magnitude of these differences was not sufficient to make the device cost-effective.

**Limitations**

Despite using multiple sources of recording of severe exacerbations, a significant number of participants failed to record levels of prednisolone in their daily diaries, which may have led to an overall under-reporting of exacerbations and rendered the trial inconclusive. The magnitude of this effect is unknown as the majority of missing doses occurred at levels that were low, when participants were likely to have remained well and exacerbation free.

**Clinical and research implications**

The types of patients who may benefit from the TLA device, and the reasons for the large reduction in exacerbation frequency in severe asthma in trials incorporating other methods of recording exacerbations, requires further exploration.
Trial registration

This trial is registered as ISRCTN46346208.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 12/33/28. The contractual start date was in May 2017. The draft report began editorial review in December 2017 and was accepted for publication in August 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Kapoor et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Honorary Professor, University of Manchester, and Senior Clinical Researcher and Associate Professor, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Director, NIHR Dissemination Centre, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk